NCT06355310View on ClinicalTrials.gov

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 27, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

February 1, 2028

Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
DRUG

Empagliflozin 10 MG

Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)

DRUG

Placebo Oral Tablet

Participants will take an identical appearing oral tablet with zero active ingredient.

Trial Locations (1)

60601

RECRUITING

Ann & Robert H Lurie Children's Hospital of Chicago, Chicago

All Listed Sponsors
lead

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER